Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxazepam is a short-acting benzodiazepine used primarily for the treatment of anxiety disorders and acute alcohol withdrawal symptoms. It also has sedative-hypnotic, anticonvulsant, muscle relaxant, and amnesic properties. Oxazepam acts as a positive allosteric modulator at the GABA-A receptor in the central nervous system, enhancing the inhibitory effect of gamma-aminobutyric acid (GABA) and thereby reducing neuronal excitability. Its pharmacokinetics are characterized by direct glucuronidation in the liver to inactive metabolites, making it suitable for elderly patients or those with impaired hepatic function. Compared to other benzodiazepines like diazepam, oxazepam has a shorter half-life and lower abuse potential due to slower absorption and brain entry[3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxazepam.